About The Study: In this nationally representative analysis, applying low-density lipoprotein cholesterol (LDL-C) goals from the 2026 American College of Cardiology/American Heart Association dyslipidemia guideline to 2021 to 2023 U.S. population data revealed substantial gaps in LDL-C control, with an increasing gradient across primary prevention categories and high proportions among adults with established atherosclerotic cardiovascular disease. These gaps were accompanied by substantial underuse of lipid-lowering therapy. These findings provide a contemporary population-level benchmark for the updated guideline framework.
Corresponding Author: To contact the corresponding author, Shady Abohashem, MD, MPH, sabohashem@mgh.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.10529)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10529?guestAccessKey=3a4d75e7-c16f-4755-a5be-0069506fa852&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026
JAMA